vs
CrossAmerica Partners LP（CAPL）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
CrossAmerica Partners LP的季度营收约是Revvity的1.1倍（$866.3M vs $772.1M），Revvity净利率更高（12.7% vs 1.2%，领先11.6%），Revvity同比增速更快（5.9% vs -8.3%），Revvity自由现金流更多（$161.8M vs $22.4M），过去两年Revvity的营收复合增速更高（9.0% vs -4.1%）
塔峰资本合伙人（TowerBrook Capital Partners）是一家总部位于伦敦和纽约的投资管理公司，2005年从索罗斯基金管理分拆独立。该机构主打私募股权及结构性机会投资，曾收购奢侈品品牌Jimmy Choo控股权，截至2025年其管理规模超250亿美元，官网公示在管投资项目共110个。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CAPL vs RVTY — 直观对比
营收规模更大
CAPL
是对方的1.1倍
$772.1M
营收增速更快
RVTY
高出14.1%
-8.3%
净利率更高
RVTY
高出11.6%
1.2%
自由现金流更多
RVTY
多$139.4M
$22.4M
两年增速更快
RVTY
近两年复合增速
-4.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $866.3M | $772.1M |
| 净利润 | $10.2M | $98.4M |
| 毛利率 | 12.4% | — |
| 营业利润率 | 3.0% | 14.5% |
| 净利率 | 1.2% | 12.7% |
| 营收同比 | -8.3% | 5.9% |
| 净利润同比 | -39.6% | 3.9% |
| 每股收益（稀释后） | $0.24 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CAPLRVTY
| Q4 25 | $866.3M | $772.1M | ||
| Q3 25 | $971.8M | $698.9M | ||
| Q2 25 | $961.9M | $720.3M | ||
| Q1 25 | $862.5M | $664.8M | ||
| Q4 24 | $944.2M | $729.4M | ||
| Q3 24 | $1.1B | $684.0M | ||
| Q2 24 | $1.1B | $691.7M | ||
| Q1 24 | $941.5M | $649.9M |
净利润CAPLRVTY
| Q4 25 | $10.2M | $98.4M | ||
| Q3 25 | $13.6M | $46.7M | ||
| Q2 25 | $25.2M | $53.9M | ||
| Q1 25 | $-7.1M | $42.2M | ||
| Q4 24 | $16.9M | $94.6M | ||
| Q3 24 | $10.7M | $94.4M | ||
| Q2 24 | $12.4M | $55.4M | ||
| Q1 24 | $-17.5M | $26.0M |
毛利率CAPLRVTY
| Q4 25 | 12.4% | — | ||
| Q3 25 | 10.8% | 53.6% | ||
| Q2 25 | 10.5% | 54.5% | ||
| Q1 25 | 10.4% | 56.5% | ||
| Q4 24 | 10.7% | — | ||
| Q3 24 | 10.3% | 56.3% | ||
| Q2 24 | 9.2% | 55.7% | ||
| Q1 24 | 8.6% | 54.6% |
营业利润率CAPLRVTY
| Q4 25 | 3.0% | 14.5% | ||
| Q3 25 | 2.9% | 11.7% | ||
| Q2 25 | 4.3% | 12.6% | ||
| Q1 25 | 0.2% | 10.9% | ||
| Q4 24 | 3.0% | 16.3% | ||
| Q3 24 | 2.5% | 14.3% | ||
| Q2 24 | 2.5% | 12.4% | ||
| Q1 24 | -1.4% | 6.8% |
净利率CAPLRVTY
| Q4 25 | 1.2% | 12.7% | ||
| Q3 25 | 1.4% | 6.7% | ||
| Q2 25 | 2.6% | 7.5% | ||
| Q1 25 | -0.8% | 6.4% | ||
| Q4 24 | 1.8% | 13.0% | ||
| Q3 24 | 1.0% | 13.8% | ||
| Q2 24 | 1.1% | 8.0% | ||
| Q1 24 | -1.9% | 4.0% |
每股收益（稀释后）CAPLRVTY
| Q4 25 | $0.24 | $0.86 | ||
| Q3 25 | $0.34 | $0.40 | ||
| Q2 25 | $0.64 | $0.46 | ||
| Q1 25 | $-0.20 | $0.35 | ||
| Q4 24 | $0.42 | $0.77 | ||
| Q3 24 | $0.27 | $0.77 | ||
| Q2 24 | $0.31 | $0.45 | ||
| Q1 24 | $-0.48 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.1M | $919.9M |
| 总债务越低越好 | $687.2M | — |
| 股东权益账面价值 | — | $7.3B |
| 总资产 | $964.7M | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CAPLRVTY
| Q4 25 | $3.1M | $919.9M | ||
| Q3 25 | $5.8M | $931.4M | ||
| Q2 25 | $9.7M | $991.8M | ||
| Q1 25 | $6.7M | $1.1B | ||
| Q4 24 | $3.4M | $1.2B | ||
| Q3 24 | $7.8M | $1.2B | ||
| Q2 24 | $5.5M | $2.0B | ||
| Q1 24 | $6.3M | $1.7B |
总债务CAPLRVTY
| Q4 25 | $687.2M | — | ||
| Q3 25 | $700.8M | — | ||
| Q2 25 | $722.7M | — | ||
| Q1 25 | $774.1M | — | ||
| Q4 24 | $763.9M | — | ||
| Q3 24 | $769.2M | — | ||
| Q2 24 | $786.7M | — | ||
| Q1 24 | $795.8M | — |
股东权益CAPLRVTY
| Q4 25 | — | $7.3B | ||
| Q3 25 | — | $7.4B | ||
| Q2 25 | — | $7.6B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.7B | ||
| Q3 24 | — | $7.9B | ||
| Q2 24 | — | $7.9B | ||
| Q1 24 | — | $7.8B |
总资产CAPLRVTY
| Q4 25 | $964.7M | $12.2B | ||
| Q3 25 | $998.9M | $12.1B | ||
| Q2 25 | $1.0B | $12.4B | ||
| Q1 25 | $1.1B | $12.4B | ||
| Q4 24 | $1.1B | $12.4B | ||
| Q3 24 | $1.1B | $12.8B | ||
| Q2 24 | $1.2B | $13.4B | ||
| Q1 24 | $1.2B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $29.4M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $22.4M | $161.8M |
| 自由现金流率自由现金流/营收 | 2.6% | 21.0% |
| 资本支出强度资本支出/营收 | 0.8% | 2.6% |
| 现金转化率经营现金流/净利润 | 2.89× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $55.8M | $509.4M |
8季度趋势，按日历期对齐
经营现金流CAPLRVTY
| Q4 25 | $29.4M | $182.0M | ||
| Q3 25 | $24.4M | $138.5M | ||
| Q2 25 | $22.6M | $134.3M | ||
| Q1 25 | $15.0M | $128.2M | ||
| Q4 24 | $11.1M | $174.2M | ||
| Q3 24 | $41.9M | $147.9M | ||
| Q2 24 | $28.9M | $158.6M | ||
| Q1 24 | $5.8M | $147.6M |
自由现金流CAPLRVTY
| Q4 25 | $22.4M | $161.8M | ||
| Q3 25 | $17.7M | $120.0M | ||
| Q2 25 | $10.8M | $115.5M | ||
| Q1 25 | $4.9M | $112.2M | ||
| Q4 24 | $3.9M | $149.8M | ||
| Q3 24 | $34.2M | $125.6M | ||
| Q2 24 | $23.6M | $136.6M | ||
| Q1 24 | $-289.0K | $129.7M |
自由现金流率CAPLRVTY
| Q4 25 | 2.6% | 21.0% | ||
| Q3 25 | 1.8% | 17.2% | ||
| Q2 25 | 1.1% | 16.0% | ||
| Q1 25 | 0.6% | 16.9% | ||
| Q4 24 | 0.4% | 20.5% | ||
| Q3 24 | 3.2% | 18.4% | ||
| Q2 24 | 2.1% | 19.7% | ||
| Q1 24 | -0.0% | 20.0% |
资本支出强度CAPLRVTY
| Q4 25 | 0.8% | 2.6% | ||
| Q3 25 | 0.7% | 2.6% | ||
| Q2 25 | 1.2% | 2.6% | ||
| Q1 25 | 1.2% | 2.4% | ||
| Q4 24 | 0.8% | 3.4% | ||
| Q3 24 | 0.7% | 3.3% | ||
| Q2 24 | 0.5% | 3.2% | ||
| Q1 24 | 0.6% | 2.7% |
现金转化率CAPLRVTY
| Q4 25 | 2.89× | 1.85× | ||
| Q3 25 | 1.79× | 2.97× | ||
| Q2 25 | 0.90× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | 0.66× | 1.84× | ||
| Q3 24 | 3.92× | 1.57× | ||
| Q2 24 | 2.33× | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CAPL
| Retail Segment | $505.3M | 58% |
| Wholesale | $360.9M | 42% |
| Other | $1.2M | 0% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
